Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2159-8290.CD-21-0191 http://scihub22266oqcxt.onion/10.1158/2159-8290.CD-21-0191 34011563!ä!34011563 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Discov 2021 ; 11 (8): 1982-1995 Nephropedia Template TP {{tp|p=34011563|t=2021. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer |pdf=|usr=}}{{34011563}} gab.com Text Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer JO: Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=34011563 #FOAvip Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4(+) and CD8(+) T-cell responses in unexposed and SARS-CoV-2-infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4(+) T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer. SIGNIFICANCE: This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population.See related commentary by Salome and Horowitz, p. 1877.This article is highlighted in the In This Issue feature, p. 1861. Twit Text FOAVip Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer ????Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=34011563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34011563 #FOAvip English Wikipedia <ref>{{Cite pmid|34011563}}</ref> Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer #MMPMID34011563 Bilich T; Roerden M; Maringer Y; Nelde A; Heitmann JS; Dubbelaar ML; Peter A; Horber S; Bauer J; Rieth J; Wacker M; Berner F; Flatz L; Held S; Brossart P; Marklin M; Wagner P; Erne E; Klein R; Rammensee HG; Salih HR; Walz JS Cancer Discov 2021[Aug]; 11 (8): 1982-1995 PMID34011563show ga Patients with cancer, in particular patients with hematologic malignancies, are at increased risk for critical illness upon COVID-19. We here assessed antibody as well as CD4(+) and CD8(+) T-cell responses in unexposed and SARS-CoV-2-infected patients with cancer to characterize SARS-CoV-2 immunity and to identify immunologic parameters contributing to COVID-19 outcome. Unexposed patients with hematologic malignancies presented with reduced prevalence of preexisting SARS-CoV-2 cross-reactive CD4(+) T-cell responses and signs of T-cell exhaustion compared with patients with solid tumors and healthy volunteers. Whereas SARS-CoV-2 antibody responses did not differ between patients with COVID-19 and cancer and healthy volunteers, intensity, expandability, and diversity of SARS-CoV-2 T-cell responses were profoundly reduced in patients with cancer, and the latter associated with a severe course of COVID-19. This identifies impaired SARS-CoV-2 T-cell immunity as a potential determinant for dismal outcome of COVID-19 in patients with cancer. SIGNIFICANCE: This first comprehensive analysis of SARS-CoV-2 immune responses in patients with cancer reports on the potential implications of impaired SARS-CoV-2 T-cell responses for understanding pathophysiology and predicting severity of COVID-19, which in turn might allow for the development of therapeutic measures and vaccines for this vulnerable patient population.See related commentary by Salome and Horowitz, p. 1877.This article is highlighted in the In This Issue feature, p. 1861. |*COVID-19[MESH] |*Neoplasms[MESH] |CD4-Positive T-Lymphocytes[MESH] |Humans[MESH] |Immunity[MESH] |Programmed Cell Death 1 Receptor[MESH]Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patien(epmc).pdf DeepDyve Pubget Overpricing